Sorin says its newly (U.S.) launched Mitroflow Valsalva Conduit allows for safer device manipulation during assembly and implantation, thus limiting cardiac surgery time
Sorin
Sorin’s Perceval™ S Bio Valve CE Indication Extended To Over 65’s
Sorin has announced CE Mark approval for extended indications of the Perceval™ S sutureless valve, expanding the market and, the company says, paving the way for adoption of Minimally Invasive Cardiac Surgery
Sorin’s Multi-Centre Sleep Apnea Monitoring/Pacemaker Study Starts Enrollment
New Sorin study evaluates sensitivity and positive predictive value of Sleep Apnea Monitoring (SAM) feature in implantable pacemakers.
Sorin Group To Acquire CV Cannula Business, CalMed
Sorin group is to acquire CalMed, Californian manufacturer of cardiovascular cannulae, in a move which will enhance the Italian company’s offering.
FDA Approval And US Launch Of Sorin’s Portfolio Of Implantable Heart Device Leads
Following CE marking earlier this year, Heart Rhythm 2012 sees Sorin announce FDA approval and US launch of its new pacing, defibrillation and left ventricular leads.
Sorin Needs To Pick Up Rhythm in 2012
Sorin’s Valve and CardioPulmonary Businesses were dragged down by Rhythm management, but overall 2011 sales held up and profits soared.
CE Mark And Launch For Sorin’s New Pacing, Defibrillation And Left Ventricular Leads
New lead portfolio combined with Sorin Group’s innovative and intelligent devices provide full-featured systems for accurate management of arrhythmias and heart failure
CE Mark For Sorin’s New Oxygenator
Sorin Group has received CE Mark approval for INSPIRE™6, the first model of an entire new family of oxygenator systems bringing improved performance and flexibility during cardiopulmonary bypass procedures in adult patients.
SORIN Q3 RESULTS SHOW GROSS MARGINS ABOVE 60%
Sorin’s profits climbed by 47.5% year on year despite sales slowdown
FIRST PATIENT ENROLLED IN SORIN IMPLANTABLE DEFIBRILLATOR STUDY
Study will evaluate the effectiveness of PARAD+™algorithm in minimizing inappropriate defibrillator shocks
SORIN GROUP LAUNCHES SONR® SENSOR BASED CARDIAC RESYNCHRONIZATION THERAPY (CRT) OPTIMIZATION SYSTEM
Sorin announced at the Venice Arrhythmias 2011 Congress, CE Mark approval and the European commercial launch of its innovative SonR CRT optimization system
SORIN GROUP INVESTS IN ENOPACE BIOMEDICAL, EARLY STAGE COMPANY FOCUSED ON INNOVATIVE SOLUTION FOR HEART FAILURE PATIENTS
Investment will drive development of a unique interventional technology for the largest unmet clinical need in the cardiovascular field
Sorin Group Announces European Market Release and First Implant of Its New-Generation Dual Chamber Implantable Cardioverter Defibrillator
Sorin Group announced today the commercial market release and first implant of its new generation PARADYM™ DR 8550 dual chamber implantable cardioverter-defibrillator (ICD).
Sorin Group And Orange Business Services To Develop Remote Monitoring Solution For Cardiac Patients
Sorin Group and Orange Business Services today announced an agreement to develop and service a remote monitoring solution for patients implanted with cardiac rhythm management devices.
Sorin Group Announces Start of Patient Enrolment in ‘Perceval S’ Sutureless Aortic Valve Clinical Trial in Europe
Sorin Group announced today the enrolment of the first three patients in a clinical trial aimed at obtaining European market approval for its ‘Perceval S’ Sutureless Aortic Heart Valve.
Sorin Group acquires Endoscopic Vessel Harvesting Business from Datascope, Inc.
Deal adds new product line to the Sorin Group’s core cardiovascular business franchise.